Cytokinetics to Present Five Aficamten Studies at ESC Congress 2024

May 15, 2024 — Cytokinetics, Inc. (Nasdaq: CYTK) has revealed five significant presentations concerning aficamten at the upcoming European Society of Cardiology Congress 2024, to be held in London from August 30 to September 2, 2024.

The first presentation, titled "Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Substudy," will be delivered by Dr. Ahmad Masri, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University. This study focuses on how aficamten affects the structural and functional changes in patients suffering from obstructive hypertrophic cardiomyopathy. Dr. Masri will present this information on August 30, 2024, during the "Cardiac Amyloidosis: Diagnosis and Outcomes" session, which will take place from 3:00-3:50 PM BST at Station 10.

The second presentation, "Clinical Application of Biomarkers in Obstructive Hypertrophic Cardiomyopathy: Insights from SEQUOIA-HCM," is set to be presented by Dr. Caroline Coats, Lead Clinician at the West of Scotland Inherited Cardiac Conditions Service and Honorary Senior Lecturer at the University of Glasgow. Dr. Coats will discuss the role of biomarkers in managing obstructive hypertrophic cardiomyopathy. Her session, titled "Novel Therapies for Hypertrophic Cardiomyopathy - Recent Developments and Future Prospects," will be part of the "Advances in Science" series and is scheduled for September 1, 2024, from 8:15-9:45 AM BST in Dublin. Dr. Coats will specifically present at 8:51 AM BST.

Dr. Ahmad Masri will also offer another significant presentation: "Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis." This study will review the safety profile of aficamten for obstructive hypertrophic cardiomyopathy patients. This presentation will be part of the same "Novel Therapies for Hypertrophic Cardiomyopathy - Recent Developments and Future Prospects" session on September 1, 2024, with Dr. Masri taking the stage again at 9:09 AM BST in Dublin.

Another notable presentation will be given by Dr. Sheila Hegde, a specialist in Cardiovascular Medicine at Brigham and Women’s Hospital. Titled "Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy," this study examines the impact of aficamten on the echocardiographic parameters in symptomatic adult patients. Dr. Hegde will present her findings on September 2, 2024, during the "Cardiac Myosin Inhibitors for Treatment of Hypertrophic Obstructive Cardiomyopathy" session from 12:00-1:00 PM BST at Science Box 3. Her specific presentation time is 12:00 PM BST.

Lastly, Dr. John A. Spertus, Professor and Clinical Director at the University of Missouri Kansas City Healthcare Institute for Innovations in Quality, will present "Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM." This study highlights the patient-reported outcomes related to aficamten treatment. Dr. Spertus will present during the same session as Dr. Hegde on September 2, 2024, at 12:10 PM BST at Science Box 3.

Cytokinetics is a biopharmaceutical company specializing in cardiovascular treatments. The company is currently developing several drug candidates, including aficamten, a cardiac myosin inhibitor, with multiple ongoing Phase 3 clinical trials such as SEQUOIA-HCM, MAPLE-HCM, ACACIA-HCM, CEDAR-HCM, and FOREST-HCM. Additionally, Cytokinetics is working on other potential treatments like omecamtiv mecarbil and CK-586, aimed at various heart conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!